Imidazotriazolopyrimidines with adenosine-antagonistic activity

US6492377B1 · kind B1 · utility

Assignee

• BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG · DE

Inventors

• Stefan Blech · Warthausen, DE
• Adrian Carter · Bingen, DE
• Wolfram Gaida · Ingelheim am Rhein, DE
• Matthias Hoffmann · Mittelbiberach, DE
• Ulrike Kuefner-Muehl · Ingelheim am Rhein, DE
• Christopher Meade · Bingen, DE
• Gerald Pohl · Gau-Algesheim, DE
• Werner Kummer · Ingelheim am Rhein, DE
• Erich Lehr · Waldalgesheim, DE
• Joachim Mierau · Mainz, DE
• Thomas Weiser · Nieder-Olm, DE

Key dates

• Filing date: Apr 26, 2000
• Grant date: Dec 10, 2002
• Expiry date: Apr 26, 2020

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D487/14
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

New imidazotriazolopyrimidine derivatives of the formula Preferred are those compounds wherein:R1 denotes methyl, which is optionally substituted by phenyloxy or pyrrole; orR1 denotes benzyl which is optionally substituted by hydroxy, methoxy, dimethylaminoethoxy or fluorine; or R1 denotes cyclopentyl, furan or phenylethyl;R2 or R3 denote ethyl, n-propyl, allyl or propargyl;R4 or R6 denote hydrogen; and,R5 denotes methyl, n-propyl, tert.butyl, cyclopentyl or norbornenyl.These are adenosine antagonists are are useful for, inter alia, the treatment of senile dementia of the Alzheimer's type.